bpHope.com on MSN

FDA Approves Risperidone Extended-Release Injectable Option for Bipolar 1 Disorder

The first under-the-skin, long-acting risperidone injection offers a new maintenance option for adults with bipolar 1 ...
Monthly Prescribing Reference

Additional injection site approved for Risperdal Consta

The FDA has approved the injection of Risperdal Consta (risperidone long-acting injection, from Janssen) into the deltoid muscle of the arm for the treatment of schizophrenia. This approval was based ...
MPR

Uzedy Approved for Maintenance Treatment of Bipolar I Disorder

Uzedy administered once every 2 months is not recommended for the maintenance treatment of bipolar I disorder. The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release ...
FierceBiotech

Ortho-McNeil-Janssen Pharmaceuticals, Inc. Release: FDA Approves New Injection Site for RISPERDAL(R) CONSTA(R) for Schizophrenia

TITUSVILLE, N.J., Oct. 9 /PRNewswire-FirstCall/ -- Patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ([risperidone] Long ...
Medscape

FDA OKs Once-Monthly Risperidone Injection for Schizophrenia

The US Food and Drug Administration has approved the first once-monthly subcutaneous injection of risperidone (Perseris, Indivior) for the treatment of schizophrenia in adults. Perseris uses an ...
Medscape

Long-Acting Risperidone Injection

Long-acting risperidone is a suspension administered by intramuscular injection in the upper-outer gluteal area. It consists of risperidone impregnated in microspheres composed of a biodegradable, ...
Drug Store News

Lupin receives FDA nod for generic Risperdal Consta

Lupin has received approval from the Food and Drug Administration for risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial and 50 mg per vial, single-dose vials.
Taiwan News

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I ...
Business Wire

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia

TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the ...
EurekAlert!

Risperdal(R) Consta(R) significantly reduces the need for institutional psychiatric care

10 February 2004 – Davos – People with schizophrenia treated with RISPERDAL® CONSTA® [risperidone long-acting injection] are significantly less likely to be admitted to hospital than before they were ...
BioWorld

Items Tagged with 'Risperdal Consta'

Luye Pharma Group Ltd. won marketing approval in China for its risperidone microspheres for injection to treat schizophrenia, which the company said is the first formulation developed by a Chinese ...